On Friday, Recursion Pharmaceuticals Inc (NASDAQ: RXRX) opened lower -4.05% from the last session, before settling in for the closing price of $4.44. Price fluctuations for RXRX have ranged from $3.79 to $12.36 over the past 52 weeks.
Annual sales at Healthcare sector company slipped by -35.28% over the past five years. Company’s average yearly earnings per share was noted 6.97% at the time writing. With a float of $431.61 million, this company’s outstanding shares have now reached $485.21 million.
Recursion Pharmaceuticals Inc (RXRX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Recursion Pharmaceuticals Inc is 17.07%, while institutional ownership is 48.82%. The most recent insider transaction that took place on Dec 19 ’25, was worth 180,000. In this transaction Chief Executive Officer of this company sold 40,000 shares at a rate of $4.50, taking the stock ownership to the 913,839 shares. Before that another transaction happened on Dec 19 ’25, when Company’s Officer proposed sale 40,000 for $4.50, making the entire transaction worth $180,000.
Recursion Pharmaceuticals Inc (RXRX) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.53 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.42) by -0.11. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.32 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 6.97% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.69% during the next five years compared to -35.28% drop over the previous five years of trading.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
Check out the current performance indicators for Recursion Pharmaceuticals Inc (RXRX). In the past quarter, the stock posted a quick ratio of 4.60. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 50.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.81, a number that is poised to hit -0.31 in the next quarter and is forecasted to reach -1.16 in one year’s time.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) saw its 5-day average volume 36.66 million, a positive change from its year-to-date volume of 29.28 million. As of the previous 9 days, the stock’s Stochastic %D was 34.07%.
During the past 100 days, Recursion Pharmaceuticals Inc’s (RXRX) raw stochastic average was set at 13.35%, which indicates a significant increase from 12.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.31 in the past 14 days, which was lower than the 0.35 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.97, while its 200-day Moving Average is $5.17. Nevertheless, the first resistance level for the watch stands at $4.44 in the near term. At $4.63, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.72. If the price goes on to break the first support level at $4.16, it is likely to go to the next support level at $4.07. Assuming the price breaks the second support level, the third support level stands at $3.88.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Key Stats
There are currently 519,838K shares outstanding in the company with a market cap of 2.22 billion. Presently, the company’s annual sales total 58,840 K according to its annual income of -463,660 K. Last quarter, the company’s sales amounted to 5,180 K and its income totaled -162,250 K.
